| Followers | 39 |
| Posts | 2870 |
| Boards Moderated | 0 |
| Alias Born | 12/06/2003 |
Sunday, March 18, 2018 8:10:02 AM
From transcript of PETX teleconference on 4thQ results 3/14/18:
https://tinyurl.com/yaacme8b
Last month and earlier this month, we attended the two largest trade conferences in the US veterinary industry, VMX in Orlando and Western Vet in Las Vegas. Based on an aggregate number of clinics that we believe have purchased NOCITA, Galliprant and/ or ENTYCE, we believe that a large majority of veterinary clinics in the US are already using a therapeutic developed by Aratana. We believe this is quite remarkable for any company to gain acceptance of one or more of its therapeutic products by approximately two-thirds of customers in an industry within a year.
That's what St. Peter said and surely with a name like that he wouldn't lie would he?
The disconnect between that statement and a casual reading of the financials is probably accounted for by the usual promotional expenses for introduction of a new drug, the lag between wholesale stocking and retail sales and even, perhaps, what seems to me unusual accounting efforts to adapt to real world conditions with a strain on resources.
ENTYCE, capromorelin oral solution is the only FDA approved therapeutic for appetite stimulation in dogs. ENTYCE mimics ghrelin, the naturally occurring hunger hormone. It is administered once daily and it travels from the mouth to the stomach then into the blood up to the hypothalamus in the brain where it stimulates eating behavior. We believe that millions of dogs present to the veterinary clinics in the US for inappetence each year.
An overlooked biggie IMO.
In December 2017, the USDA's Center for Veterinary Biologics granted Aratana conditional licensure for canine osteosarcoma vaccine...In the past few weeks, Aratana sold its first dose of AT-014 to a study site.
GRRR!
That extended study is an atrocity.
FACT: Way back when I was younger and had much to learn about the obstinacy, ignorance and stupidity of regulators and their fawning supplicants, an idealistic scientist managed to get FDA approval for a vaccine adjuvant treating surface tumors on horses. Dr. Ribi's detoxified cell wall skeletons had much in common with Prof. Paterson's superior live Listeria vaccine adjuvant but didn't have a deadly antigen like HER2/NEU.
PETX recognized ADXS' spurious franchise/construct for the therapeutic vaccine it is and surely the threat of the HER2 antigen that has been documented in killing a handful of women being treated for breast cancers is of minor concern in dogs with an osteosarcoma having a near 100% fatality rate. I have found no reliable (nor even unreliable) statistics on the matter.
Anyway good conference call with a lot of hard questioning.
Best, Terry
https://tinyurl.com/yaacme8b
Last month and earlier this month, we attended the two largest trade conferences in the US veterinary industry, VMX in Orlando and Western Vet in Las Vegas. Based on an aggregate number of clinics that we believe have purchased NOCITA, Galliprant and/ or ENTYCE, we believe that a large majority of veterinary clinics in the US are already using a therapeutic developed by Aratana. We believe this is quite remarkable for any company to gain acceptance of one or more of its therapeutic products by approximately two-thirds of customers in an industry within a year.
That's what St. Peter said and surely with a name like that he wouldn't lie would he?
The disconnect between that statement and a casual reading of the financials is probably accounted for by the usual promotional expenses for introduction of a new drug, the lag between wholesale stocking and retail sales and even, perhaps, what seems to me unusual accounting efforts to adapt to real world conditions with a strain on resources.
ENTYCE, capromorelin oral solution is the only FDA approved therapeutic for appetite stimulation in dogs. ENTYCE mimics ghrelin, the naturally occurring hunger hormone. It is administered once daily and it travels from the mouth to the stomach then into the blood up to the hypothalamus in the brain where it stimulates eating behavior. We believe that millions of dogs present to the veterinary clinics in the US for inappetence each year.
An overlooked biggie IMO.
In December 2017, the USDA's Center for Veterinary Biologics granted Aratana conditional licensure for canine osteosarcoma vaccine...In the past few weeks, Aratana sold its first dose of AT-014 to a study site.
GRRR!
That extended study is an atrocity.
FACT: Way back when I was younger and had much to learn about the obstinacy, ignorance and stupidity of regulators and their fawning supplicants, an idealistic scientist managed to get FDA approval for a vaccine adjuvant treating surface tumors on horses. Dr. Ribi's detoxified cell wall skeletons had much in common with Prof. Paterson's superior live Listeria vaccine adjuvant but didn't have a deadly antigen like HER2/NEU.
PETX recognized ADXS' spurious franchise/construct for the therapeutic vaccine it is and surely the threat of the HER2 antigen that has been documented in killing a handful of women being treated for breast cancers is of minor concern in dogs with an osteosarcoma having a near 100% fatality rate. I have found no reliable (nor even unreliable) statistics on the matter.
Anyway good conference call with a lot of hard questioning.
Best, Terry
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
